Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMO7MTX)

• Drug Name: N-propylnorapomorphine Drug Info
• Synonyms: N-n-Propylnorapomorphine; 4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-propyl-; 57559-68-9; Propyl-norapomorphine; Propylnorapomorphine; 6-Propyl-5,6,6a,7-tetrahydro-4H-dibenzo(de,g)quinoline-10,11-diol; (+-)-N-n-Propylnorapomorphine; 10,11-Dihydroxy-6-propylnoraporphine; AC1L1IVU; GTPL934; SCHEMBL249729; R(-)-PROPYLNORAPOMORPHINE; 6-Propyl- 5,6,6a,7-tetrahydro-4H-dibenzo(de,g)quinoline-10,11-diol
• Cross-matching ID:
  PubChem CID: 167715
  ChEBI ID: CHEBI:92234
  CAS Number: CAS 18426-20-5
  TTD Drug ID: DMO7MTX

Molecule-Related Drug Atlas

Drug(s) Targeting Dopamine D3 receptor (D3R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cariprazine	DMJYDVK	Bipolar disorder	6A60	Approved	[4]
Pramipexole	DMNMW9R	Parkinson disease	8A00.0	Approved	[5]
Ropinirole	DMA6S1D	Parkinson disease	8A00.0	Approved	[5]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[6]
P2B-001	DM9PVHX	Parkinson disease	8A00.0	Phase 3	[7]
RP5063	DMKUE8O	Schizophrenia	6A20	Phase 2	[8]
ONC201	DMM5SCF	Endometrial cancer	2C76	Phase 2	[9]
TAK-906	DMBQD9H	Diabetic gastroparesis	DA41.00	Phase 2	[10]
GSK598809	DMGU05N	Drug abuse	6C4G.1Z	Phase 2	[11]
GSK618334	DMJPXZ4	Drug abuse	6C4G.1Z	Phase 1	[11]

Drug(s) Targeting Dopamine D1 receptor (D1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenyltoloxamine	DMKAEQW	Allergy	4A80-4A85	Approved	[12]
Pergolide	DM14MAE	Parkinson disease	8A00.0	Approved	[5]
Methylergonovine	DMBEX4O	Spontaneous abortion	JA00.0	Approved	[13]
Fenoldopam	DMFAOKP	Hypertension	BA00-BA04	Approved	[14]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[15]
Ecopipam	DMS9R43	Cocaine addiction	6C45.2	Phase 3	[16]
DAS-431	DMM3BPL	Dementia	6D80-6D86	Phase 2	[17]
Dihydrexidine	DMACPQO	Psychotic disorder	6A20-6A25	Phase 1/2	[18]
Lu AF28996	DMY572G	Parkinson disease	8A00.0	Phase 1	[19]
BAM-1110	DMPMKUF	Parkinson disease	8A00.0	Discontinued in Phase 2	[20]

Drug(s) Targeting Dopamine D5 receptor (D5R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenyltoloxamine	DMKAEQW	Allergy	4A80-4A85	Approved	[12]
LE-300	DMGJL16	Schizophrenia	6A20	Preclinical	[21]
ZD-3638	DM6M9GC	Schizophrenia	6A20	Terminated	[21]
GMC-283	DMT1RH6	Schizophrenia	6A20	Terminated	[21]
(+/-)-nantenine	DM0L3GE	Discovery agent	N.A.	Investigative	[22]
ISOCLOZAPINE	DM52CPU	Discovery agent	N.A.	Investigative	[23]
FLUMEZAPINE	DMW0HOG	Discovery agent	N.A.	Investigative	[24]
ISOLOXAPINE	DMH1BN4	Discovery agent	N.A.	Investigative	[25]
1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine	DMOL2Y0	Discovery agent	N.A.	Investigative	[23]
1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine	DMD2NXL	Discovery agent	N.A.	Investigative	[12]

Drug(s) Targeting Dopamine D2 receptor (D2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[26]
Haloperidol	DM96SE0	Delirium		Approved	[27]
Perphenazine	DMA4MRX	Schizophrenia	6A20	Approved	[28]
Perazine	DM2AOTZ	Psychotic disorder	6A20-6A25	Approved	[29]
Domperidone	DMBDPY0	Gastrointestinal disease	DE2Z	Approved	[30]
Levodopa	DMN3E57	Parkinson disease	8A00.0	Approved	[31]
Quetiapine	DM1N62C	Anorexia nervosa cachexia	6B80	Approved	[32]
Pimozide	DMW83TP	Schizophrenia	6A20	Approved	[33]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[34]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[35]

Drug(s) Affected By Somatotropin (GH1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Polyethylene glycol	DM4I1JP	Constipation	DD91.1	Approved	[36]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[37]
Adenosine triphosphate	DM79F6G	Malnutrition	5B50-5B71	Approved	[38]
Cyproheptadine	DM92AH3	Allergic rhinitis	CA08.0	Approved	[39]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[40]
Sodium oxybate	DMBOV5P	Narcolepsy	7A20	Approved	[41]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[36]
Connexyn	DMF29Q5	Attention deficit hyperactivity disorder	6A05.Z	Approved	[42]
Gamma Hydroxybutyric Acid	DMGBKVD	Narcolepsy	7A20	Approved	[43]
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[44]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D1 receptor (D1R)	TTZFYLI	DRD1_HUMAN	Agonist	[1]
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Inhibitor	[2]
Dopamine D3 receptor (D3R)	TT4C8EA	DRD3_HUMAN	Agonist	[2]
Dopamine D5 receptor (D5R)	TTS2PH3	DRD5_HUMAN	Agonist	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Somatotropin (GH1)	OT92RTRD	SOMA_HUMAN	Protein Interaction/Cellular Processes	[3]

References

• [1] Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature. 1991 Apr 18;350(6319):614-9.
• [2] A functional test identifies dopamine agonists selective for D3 versus D2 receptors. Neuroreport. 1995 Jan 26;6(2):329-32.
• [3] Treatment of Parkinson's disease with aporphines. Possible role of growth hormone. N Engl J Med. 1976 Mar 11;294(11):567-72. doi: 10.1056/NEJM197603112941101.
• [4] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
• [7] Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18.
• [11] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [12] Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
• [13] Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20.
• [14] Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost. Yakugaku Zasshi. 2008 Jul;128(7):1023-9.
• [15] Clinical pipeline report, company report or official report of Lundbeck.
• [16] A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome.Clin Neuropharmacol.2014 Jan-Feb;37(1):26-30.
• [17] Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001 Fall;7(3):305-16.
• [18] trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization o... J Med Chem. 2006 Nov 16;49(23):6848-57.
• [19] Clinical pipeline report, company report or official report of Lundbeck
• [20] Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinso... J Pharmacol Exp Ther. 1998 Jul;286(1):228-33.
• [21] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [22] Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
• [23] Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1982 Jul;25(7):855-8.
• [24] Effects of conformationally restricted 4-piperazinyl-10H-thienobenzodiazepine neuroleptics on central dopaminergic and cholinergic systems. J Med Chem. 1982 Oct;25(10):1133-40.
• [25] Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6.
• [26] The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
• [27] Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
• [28] CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
• [29] Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
• [30] Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
• [31] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
• [32] Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
• [33] [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
• [34] Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
• [35] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [36] Metal-catalyzed oxidation of human growth hormone: modulation by solvent-induced changes of protein conformation. J Pharm Sci. 2001 Jan;90(1):58-69. doi: 10.1002/1520-6017(200101)90:1<58::aid-jps7>3.0.co;2-w.
• [37] Assessment of MK-912, an alpha 2-adrenoceptor antagonist, with use of intravenous clonidine. Clin Pharmacol Ther. 1989 Jul;46(1):103-9. doi: 10.1038/clpt.1989.113.
• [38] Phosphatidylinositol 4-OH kinase is a downstream target of neuronal calcium sensor-1 in enhancing exocytosis in neuroendocrine cells. J Biol Chem. 2003 Feb 21;278(8):6075-84. doi: 10.1074/jbc.M204702200. Epub 2002 Dec 5.
• [39] [Toxicity of cyproheptadine. Side effects and accidental overdosage (author's transl)]. Monatsschr Kinderheilkd (1902). 1978 Mar;126(3):123-6.
• [40] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [41] Failure of gammahydroxy butyric acid to stimulate growth hormone secretion in cocaine addicts. Neuropeptides. 1997 Oct;31(5):459-62. doi: 10.1016/s0143-4179(97)90040-8.
• [42] Effect of centrally acting alpha-adrenergic agonists on sympathetic nervous system function in humans. Hypertension. 1984 Sep-Oct;6(5 Pt 2):II57-62. doi: 10.1161/01.hyp.6.5_pt_2.ii57.
• [43] Thyrotropin-releasing hormone-induced GH release after cocaine withdrawal in cocaine addicts. Neuropeptides. 1999 Dec;33(6):522-5. doi: 10.1054/npep.1999.0773.
• [44] Effects of cortisol and cocaine on plasma prolactin and growth hormone levels in cocaine-dependent volunteers. Addict Behav. 2005 May;30(4):859-64. doi: 10.1016/j.addbeh.2004.08.019.